The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.